OvaScience Inc. (NASDAQ: OVAS)
According to the law firm press release, the complaint alleges that defendants caused the Company to issue false and misleading statements and/or fail to disclose, among other things, that: (1) the science behind AUGMENT had not been scientifically validated; (2) the Company was unable to achieve the purported success rates it claimed; (3) the reasons why the Company moved its studies outside of the United States; and (4) that at all relevant times, the Company’s profitability and prospects were false and misleading.